Your browser doesn't support javascript.
loading
Engineering in vitro immune-competent tissue models for testing and evaluation of therapeutics.
Hammel, Jennifer H; Zatorski, Jonathan M; Cook, Sophie R; Pompano, Rebecca R; Munson, Jennifer M.
Afiliación
  • Hammel JH; Fralin Biomedical Research Institute and Department of Biomedical Engineering and Mechanics, Virginia Tech, Roanoke, VA 24016, USA. Electronic address: jm4kt@vt.edu.
  • Zatorski JM; Department of Chemistry, University of Virginia, Charlottesville, VA 22904, USA.
  • Cook SR; Department of Chemistry, University of Virginia, Charlottesville, VA 22904, USA.
  • Pompano RR; Department of Chemistry, University of Virginia, Charlottesville, VA 22904, USA; Department of Biomedical Engineering, University of Virginia, Charlottesville, VA 22904, USA; Carter Immunology Center and UVA Cancer Center, University of Virginia School of Medicine, Charlottesville, VA 22903, USA. El
  • Munson JM; Fralin Biomedical Research Institute and Department of Biomedical Engineering and Mechanics, Virginia Tech, Roanoke, VA 24016, USA.
Adv Drug Deliv Rev ; 182: 114111, 2022 03.
Article en En | MEDLINE | ID: mdl-35031388
Advances in 3D cell culture, microscale fluidic control, and cellular analysis have enabled the development of more physiologically-relevant engineered models of human organs with precise control of the cellular microenvironment. Engineered models have been used successfully to answer fundamental biological questions and to screen therapeutics, but these often neglect key elements of the immune system. There are immune elements in every tissue that contribute to healthy and diseased states. Including immune function will be essential for effective preclinical testing of therapeutics for inflammatory and immune-modulated diseases. In this review, we first discuss the key components to consider in designing engineered immune-competent models in terms of physical, chemical, and biological cues. Next, we review recent applications of models of immunity for screening therapeutics for cancer, preclinical evaluation of engineered T cells, modeling autoimmunity, and screening vaccine efficacy. Future work is needed to further recapitulate immune responses in engineered models for the most informative therapeutic screening and evaluation.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ensayos de Selección de Medicamentos Antitumorales / Ingeniería de Tejidos / Sistema Inmunológico / Neoplasias / Antineoplásicos Tipo de estudio: Prognostic_studies Idioma: En Revista: Adv Drug Deliv Rev Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ensayos de Selección de Medicamentos Antitumorales / Ingeniería de Tejidos / Sistema Inmunológico / Neoplasias / Antineoplásicos Tipo de estudio: Prognostic_studies Idioma: En Revista: Adv Drug Deliv Rev Asunto de la revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2022 Tipo del documento: Article